The object
Michael Cima co-developed the implantable intravesical drug-delivery system that became TAR-200, a device that delivers chemotherapy locally in the bladder. MIT reports that the system began in Cima's lab, was co-developed through TARIS Biomedical and received FDA approval in 2025; MIT's current profile documents his implantable diagnostic and delivery-device research.
What Michael did
Co-developed the implantable intravesical drug-delivery system that became TAR-200 for bladder-cancer treatment.
Why it matters
TAR-200 turned a prolonged local drug-delivery concept into an FDA-approved device for an aggressive form of bladder cancer.
Living-status check
MIT News reported in September 2025 on the FDA approval of technology conceived in Cima's lab, and MIT's current Koch Institute profile lists his active device research.